All In Biotech

NDA 021306 · Knoa Pharma

Butrans

Buprenorphine · Transdermal · Partial Opioid Agonist

Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Jun 30, 2010

Approved uses

2

Original approval plus efficacy supplements

Registered trials

512

125 Phase 3, 43 recruiting

FAERS reports

84,822

53,931 serious, 26,428 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BUPRENORPHINE TRANSDERMAL SYSTEM Addiction, Abuse, and Misuse Because the use of buprenorphine transdermal system exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1) ] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of buprenorphine transdermal system, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of buprenorphine transdermal system are essential. Misuse or abuse of buprenorphine transdermal system by chewing, swallowing, snorting,...

What it is approved for

From the label in effect May 29, 2026.

Buprenorphine transdermal system is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1) ] , reserve opioid analgesics, including buprenorphine transdermal system, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Buprenorphine transdermal system is not indicated as an as-needed (prn) analgesic. Buprenorphine transdermal system is a partial opioid agonist indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including buprenorphine transdermal system for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 ) Buprenorphine transdermal system is not indicated as an as-needed (prn) analgesic. ( 1 )

Mechanism: Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa- opioid receptors, an agonist at delta-opioid receptors, and a partial agonist at ORL-1 (nociceptin) receptors. The contributions of these actions to its analgesic profile are unclear.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • BUTRANS · BUPRENORPHINE 15MCG/HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
  • BUTRANS · BUPRENORPHINE 10MCG/HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
  • BUTRANS · BUPRENORPHINE 7.5MCG/HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
  • BUTRANS · BUPRENORPHINE 20MCG/HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
  • BUTRANS · BUPRENORPHINE 5MCG/HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Buprenorphine" as an intervention, any sponsor and status, largest first.

All 512 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death13,389
  • drug dependence12,078
  • overdose10,916
  • toxicity to various agents10,759
  • pain8,180
  • drug ineffective6,221
  • drug withdrawal syndrome5,754
  • emotional distress5,448
  • nausea4,248
  • drug abuse3,588
  • inadequate analgesia3,049
  • application site rash3,025

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
200534
20063
20072
20084
200937
201096
2011426
2012667
201313,502
20145,252
20154,559
20163,033
20174,504
201822,273
20192,613
20203,991
20218,152
20225,243
20232,351
20242,866
20253,245
20261,966

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Butrans (Buprenorphine)

2024 spending

$10.8M

Beneficiaries

5,870

25,786 claims

Per beneficiary

$1,840

$102.43 per unit

View as table
YearSpending
2020$36,897,930
2021$28,027,195
2022$24,817,188
2023$23,248,673
2024$10,800,854

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,775 on PubMed

Sponsor: Knoa Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.